12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Company News  |  Other News

Medivir infectious news

Medivir said it is discontinuing its preclinical HCV NS5A protein inhibitor program to focus on its preclinical program of nucleotide-based HCV polymerase inhibitors. The company said it made...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >